Should_a_drug_manufacturer_disclose the side eeffects of a drug to potential patients natural langua

Document Content and Description Below

1. Reuters Knowledge Direct, October 31, 2014, Accredo Health Inc, 1640 CENTURY CENTER PARKWAY, SUITE 101, MEMPHIS, , TN, 38134 ... reimbursement services and delivery services. The Company addresse... s the needs of the manufacturers by providing specialized services that facilitate product launch and patient acceptance, including the collection of timely drug utilization and patient compliance information, patient education and monitoring through the use of written materials and telephonic consultation, reimbursement expertise and overnight drug delivery. It has designed its specialty retail pharmacy services to focus primarily on biotechnology injectable drugs that are used on a recurring basis to treat chronic and ... ... specialty retail pharmacy and related services that address the needs of patients with chronic diseases, including Multiple Sclerosis, Gaucher Disease, ... ... respiratory syncytial virus. The Company has agreements with 15 biopharmaceutical manufacturers to buy drugs and to provide varying degrees of specialty retail pharmacy services ... ... not exclusive, Accredo generally is a recommended provider of the manufacturer's drug to patients and physicians. These agreements also contain favorable pricing from the manufacturer, and in many cases, compensate the Company for its specialized ... ... Greensboro, North Carolina and Liberty Township, Ohio, serving patients in 30 states. Sale and Delivery of Drugs Accredo sells and provides timely delivery of drugs and ancillary supplies directly to the patient or the patient's physician in package specially designed to maintain appropriate ... ... contains all of the supplies required for administration in the patient's home or in other alternate sites. Substantially all ... ... Pharmacy Services The Company offers customized services to biopharmaceutical manufacturers designed to meet specific needs that arise at various ... ... related to strategic pricing decisions; analyses and information to assist manufacturers in evaluating payor mix and pricing strategies for their new drugs; testing of a manufacturer's packaging to assess maintenance of product temperatures and to determine whether the packaging ... ... conditions; advice on injection and infusion supplies related to the drug therapy and assistance in procuring supplies and customized packaging ... ... in learning how to safely and effectively administer a drug, including sterilization techniques, supplies needed and infusion time ... ... launch, the Company offers clinical hotlines that allow the physician or patient caregiver to inquire about product usage, adverse drug reactions and other clinical questions; reimbursement hotlines for patients and healthcare professionals; support for manufacturers' patient assistance programs for patients without the financial ability to otherwise acquire needed drugs and services; replacement drug and supply programs that replenish patients' inventory of products or supplies that become damaged; home care coordination programs that provide patient assistance in training, identify home care providers and ... ... clinical information to all caregivers, and triage services that refer patients to the appropriate provider based on the patients' insurance provider network. Results of the Company's interaction with patients, which is primarily via telephone, are coded to protect privacy and tracked to compile valuable information, including side effects, drug interactions, administration problems, supply issues, physician prescription ... ... non-compliance. Accredo will also report on adverse drug reactions, log the occurrence and complete an initial preliminary report of the occurrence to Page 1assist manufacturers in completing adverse event reports in a ... ... variety of additional reports that can be customized to meet specific manufacturers' needs. Examples of reports include sales by physician, ... ... by zip code, sales trending, first-time patient orders, Medicaid and Medicare sales, inventory status and reasons for patient discontinuations. Due to the nature of the data it collects, Accredo has ... ... procedures designed to ensure compliance with laws regarding confidentiality of patient information. Clinical Services Accredo works with the patient and the patient's physician to implement the prescribed plan of care. Each patient is assigned to a team consisting of a pharmacist, a ... ... certain therapies, a registered Nurse. Generally, each patient's team members specialize only in that patient's disease and work only with payors and providers in that patient's geographic region. In helping to implement the prescribed plan of care, the Company helps patients understand their medication and treatment program; helps patients manage potential side effects and adverse reactions that may occur so that patients are less likely to discontinue therapy; helps coordinate backup care in the event of a medical emergency, and helps patients establish an inventory management and record keeping system. The Company also assists patients and their families in coping with a variety of difficult emotional and ... ... by their diseases. In addition, it participates in patient advocacy organizations, assists in the formation of patient support groups, advocates legislation to advance patient interests and publishes newsletters and educational materials for its patients. Reimbursement Services By focusing on specific chronic ... ... significant expertise in managing reimbursement issues related to the patient's condition and treatment program. Due to the long duration and high ... ... insurance is a continual concern for chronically ill patients and their families. Generally, the Company contacts the payor prior to each shipment to determine the patient's health plan coverage and the portion of costs that the payor will ... ... part of an initial consultation, Accredo can assist the patient in planning for alternate coverage, if necessary. From time to ... ... substantially eliminates the claims submission process for most patients. The Company's competitors include specialty pharmacy distributors such as Caremark ... CHRONIC DISEASES (96%); RETAIL PHARMACEUTICALS (95%); DRUG INTERACTIONS & SIDE EFFECTS (95%); HEMOPHILIA (95%); PHARMACIES & DRUG STORES (94%); PHARMACIES (94%); DISEASES & DISORDERS (92%); ... ... HEALTH CARE (91%); PRICE MANAGEMENT (91%); ADVERSE DRUG EVENT REPORTING (91%); HEALTH INSURANCE (91%); NURSES & ... ... 90%); BLOOD DISORDERS (90%); BIOTECHNOLOGY INDUSTRY (90%); PATIENT PRIVACY (90%); NEW PRODUCTS (90%); HOLDING COMPANIES (90%); DRUG DELIVERY SYSTEMS (90%); CONSULTING SERVICES (90%); INVENTORY ... ... 90%); RESPIRATORY DISEASE (90%); TRENDS (90%); PRESCRIPTION DRUGS (90%); TEACHING MATERIALS & MEDIA (90%); VIRUSES (89%); ... 2. SGA Executive Tracker, LAST UPDATED: September 9, 2014, Kai Pharmaceuticals, Inc., 270 Littlefield Avenue, South San Francisco, , CA, 94080 * * * * * * * * * * DESCRIPTION * * * * * * * * * * INDUSTRY TYPE: Drug Manufacturers - Major KAI is a drug discovery and development company with novel clinical-stage programs ... Page 2... Phase 2b study (PROTECTION AMI) designed to assess the effect of KAI-9803 on reducing myocardial injury in heart attack patients. KAI`s second clinical program, KAI-1678, has the potential to address both the inflammatory and neuropathic pain markets and currently is ... ... protein interactions and delivery of peptides into the cell. This approach has broad potential and has been validated clinically. The Company has applied its core expertise to discover ... 3. GlobalData - Events, October 22, 2014, Mosaiques Diagnostics And Therapeutics AG, Mellendorfer Strasse 7-9, Hannover, 30625 * * * * * * * * * * EVENTS * * * * * * * * * * Mosaiques And U.S. Fda Describe Detection Of Drug-Induced Side Effects In Early Phase Animal Models May 06, 2009 May 6, 2009 -- Rockville/Hannover - Drug-induced toxicity represents a significant problem in ... ... Over 100,000 people die per year from adverse effects of medications in the U.S. (Starfield, JAMA 2000, 284: 483- 485). This has led to an intense awareness of drug-induced side effects, which may hamper the development of new therapeutic agents. Initial assessment of possible side effects in animal models is certainly preferred over discovering side effects in a clinical study - if not worse after ... ... technology by the early and reliable assessment of druginduced side effects in animal models. The data clearly indicate that CE/MS analysis is able to display drug-induced changes in the urinary proteome. To reveal drug-induced alterations (or the absence thereof) with high statistical significance opens an avenue towards screening for potential side effects with limited or reasonable effort during preclinical research.Prof. ... ... CSO, said: We are aiming to reduce or even prevent adverse effects of drugs by implementing our technology in (pre)clinical testing. This ... ... analysis is a very valuable tool not limited to assessing drug toxicity and unwanted side-effects in preclinical investigations, but also to reduce the risk for appearance of such side effects later in clinical studies, or even after approval. This ... ... entitled: Profiling of rat urinary proteomic patterns associated with drug-induced nephrotoxicity using capillary electrophoresis coupled with mass spectrometry as a potential model for detection of drug-induced adverse effects. The project was funded in part by grants of the Federal ... ... Union. Profiling Of Rat Urinary Proteomic Patterns Associated With Drug-Induced Nephrotoxicity Using Capillary Electrophoresis Coupled With Mass Spectrometry As A Potential Model For Detection Of Drug-Induced Adverse Effects May 05, 2009 May 5, 2009 -- Our study strongly suggests that (drug-induced) nephrotoxicity can be detected with high accuracy in laboratory rodents using urinary proteome analysis. The effects observed are very similar to those seen in corresponding human diseases and similar approaches may be very helpful in evaluating drug-induced organ damage in preclinical animal models. Mosaiques And U.S. Food And Drug Administration (Fda) Sign Contract For Collaboration In Discovery And Validation Of Biomarkers For Assessment Of Drug Toxicity Feb 20, 2009 February 20, 2009 -- ... ... announces the signing of a collaborative agreement with the U.S. Food and Drug Administration. The aim of this collaborative project is the identification and validation of protein- and peptide biomarkers for drug toxicity in urine. Based on preliminary experiments, it is anticipated that toxic effects of drugs will result in indicative changes in the proteome of ... ... gross pathological changes become apparent. The U.S. Food and Drug Administration will contribute know how on drugs, expected drug toxicities, as Page 3well as conduction animals studies. mosaiques diagnostics ... ... validated, will enable a more accurate assessment of potential drug toxicity, consequently identification of potentially serious side effects of therapeutics at an early stage of development and before ... ... Conrads, said: One of the key issues to reduce toxicity of drugs is being able to quickly and accurately access severe side effects in early developmental phases. This is no simple matter and the ... ... speeds up this process and lays the foundation for safer drugs and personalized medicine.mosaiques' founder and CSO, Prof. Dr. ... ... currently available. We are aiming to reduce or even prevent adverse effects of drugs by implementing our technology in (pre)clinical testing. This agreement with the FDA underlines the potential of the protein pattern technology for modern medicine and appropriate ... ... a blinded prospective multicenter study with more than 500 patients in order to improve prostate cancer diagnosis. Improved Safety For Leukaemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation Mar ... ... only curative treatment for leukaemia in adult patients, but carries the risk of severe, even lethal complications. The ... ... international, blinded, multicenter clinical study including 141 patients, and demonstrated the high value of their method based on clinical ... ... GvHD). The fast initiation of therapeutic measures is crucial to survival of the patient. The innovative technique enables the early detection and prevention of GvHD, ... ... methods. This is an inestimable gain of time for treatment of patients, a lifesaving advantage. Furthermore, the success of therapy can be ... ... costs of aHSCT amounts up to 150 Euro per patient. In the case of complications, the costs may double or triple. ... ... life saving aHSCT would become unaffordable for most patients. The now available diagnostic method of rapid and early diagnosis of ... ... complication-associated costs. It is to be hoped that the beneficial cost effects will change the opinion of IQWiG and the life saving sHSCT therapy can be available for all patients, not only the wealthy. * * * * * * * * * * OTHER AVAILABLE REPORTS * * * * * * * * * * ... ... DEVELOPMENT (89%); INVESTIGATIONS (87%); TOXICOLOGY (78%); ADVERSE DRUG EVENT REPORTING (78%); PHARMACEUTICALS INDUSTRY (78%); DRUG INTERACTIONS & SIDE EFFECTS (77%); RESEARCH & DEVELOPMENT (75%); EXPERIMENTATION & RESEARCH (74%); ... 4. Zoom Company Information, October 2014, Rye Hospital Center, 754 Boston Post Road Ny, Rye, , NY, 10580 ... Center, our clinical eye is focused especially on the adolescent patient's individual metabolic profile. Because of the potential of iatrogenic pancreatitis and non-reversible diabetes mellitus, from use of the ... ... body-mass index are monitored regularly. Also, since many of these drugs may dangerously prolong the QTc interval, patients receive serial EKGs; and careful attention is paid to simultaneous ... ... antibiotics, anti-allergy, antiarrythmics, migraine and over-the-counter drugs which, when added to these psychotropics can lead to fatal tachyarrhythmias. Indeed, ... ... careful attention to emergence of the serotonin syndrome, its insulin resistence and the potential for rebound diabetogenic effects on the patient when the medications are changed or stopped. Pharmacokinetic drug interactions are potential sources of adverse outcomes in our patients. Over the past several years, we have been clinically focused on the [Show More]

Last updated: 1 year ago

Preview 1 out of 1188 pages